Original paperRheumatoid arthritis and cancer risk
References (30)
- et al.
Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
J Chron Dis
(1978) - et al.
Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort
Am J Med
(1985) Cancer and rheumatoid arthritis: epidemiologic considerations
Am J Med
(1985)- et al.
Cancer in rheumatoid arthritis: a prospective long-term study of mortality
Am J Med
(1985) - et al.
Association of non-Hodgkin's lymphoma with rheumatoid arthritis [letter]
Am J Med
(1986) - et al.
Mortality among arthritics
J Chronic Dis
(1976) Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens
Am J Med
(1985)- et al.
Determinants of cell type in patients with cancer of the lungs
Chest
(1990) Rheumatoid arthritis
Immunol Ser
(1993)- et al.
Epidemiology of rheumatoid arthritis: update
Epidemiol Rev
(1990)
Potential role of Epstein-Barr virus in Sjögren's syndrome and rheumatoid arthritis
J Rheumatol Suppl
(1992)
Incidence of cancer among patients with rheumatoid arthritis
J Natl Cancer Inst
(1993)
Cited by (362)
Naringenin nanoparticles targeting cyclin B1 suppress the progression of rheumatoid arthritis-associated lung cancer by inhibiting fibroblast-to-myofibroblast transition
2024, International Journal of Biochemistry and Cell BiologyRheumatoid arthritis and risk of lung cancer: Meta-analysis and Mendelian randomization study
2021, Seminars in Arthritis and RheumatismCancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis
2020, Pharmacological ResearchCitation Excerpt :Evidence-based recommendations for PsA treatment with NSAIDs, conventional synthetic DMARDs, and biological agents have been published but, although the clinical efficacy of biological treatment has been clearly established, there is still uncertainty regarding its potential adverse effects [68]. The risk of malignancy associated with PsA is still a controversial subject, but RA and other inflammatory joint diseases have been associated with an increased prevalence [23,69–71]. The aim of one of the first studies on the subject was to determine the prevalence of malignancy in 665 PsA patients prospectively followed up by the University of Toronto Psoriatic Arthritis Clinic from 1978 to 2004.
JAK-Inhibitors – A Story of Success and Adverse Events
2024, Open Access Rheumatology: Research and ReviewsThe safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials
2024, Journal of the European Academy of Dermatology and Venereology
Copyright © 1996 Published by Elsevier Ltd.